CaroGen Corporation develops hepatitis B immunotherapy for patients facing long-term treatment
CaroGen Corporation is developing an immunotherapy for people with chronic hepatitis B that aims to prompt an immune response against the virus. The World Health Organization says most people who start treatment with existing antivirals must continue it for life. On October 20, 2026, the FDA approved Hibsago (bepirovirsen) with existing antiviral therapy for certain adults without cirrhosis. Some patients may later stop all hepatitis B treatment if they meet health and laboratory requirements. CaroGen’s CARG-201 remains investigational, with patient benefit still to be established.
From immune response to a planned human study
CaroGen's candidate, CARG-201, is built on a platform called AVIDIO. It uses self-amplifying RNA to produce two hepatitis B antigens, which are intended to help stimulate an immune response.
The company aims for a functional cure, but CARG-201 remains investigational and has not been approved as a treatment.
CaroGen reports that the US Food and Drug Administration authorized its investigational new drug application in June 2026, after a clinical hold was removed following review of additional nonclinical safety studies.
The company describes a Phase 1/1b dose-escalation study in patients already on stable antiviral therapy as the next step. Its planned primary measures are safety and the maximum tolerated dose, alongside assessments of immune and hepatitis B markers.
The distinction matters commercially as well as clinically: evidence from people could inform whether the candidate merits further development, but permission to study it is not evidence that it benefits patients.
WHO estimates that 240 million people worldwide were living with chronic hepatitis B in 2024, and about 10 million were receiving antiviral treatment. Those figures describe a global health burden, not a count of potential buyers for CARG-201.